Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $80
Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and raises the price target from $77 to $80.
Inari Medical Q4 EPS $(0.11) Beats $(0.17) Estimate, Sales $107.77M Beat $104.84M Estimate
Inari Medical (NASDAQ:NARI) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 35.29 percent. This is a 650 percent decrease over earnings of $0.02 per share from the
Analyst Expectations for Inari Medical’s Future
Within the last quarter, Inari Medical (NASDAQ:NARI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Morgan Stanley Maintains Overweight on Inari Medical, Lowers Price Target to $83
Morgan Stanley analyst Cecilia Furlong maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from $95 to $83.
Analyst Ratings for Inari Medical
Analysts have provided the following ratings for Inari Medical (NASDAQ:NARI) within the last quarter:
BTIG Maintains Buy on Inari Medical, Lowers Price Target to $97
BTIG analyst Marie Thibault maintains Inari Medical (NASDAQ:NARI) with a Buy and lowers the price target from $100 to $97.
Jefferies Initiates Coverage On Inari Medical with Buy Rating, Announces Price Target of $88
Jefferies analyst Matthew Taylor initiates coverage on Inari Medical (NASDAQ:NARI) with a Buy rating and announces Price Target of $88.
Where Inari Medical Stands With Analysts
Analysts have provided the following ratings for Inari Medical (NASDAQ:NARI) within the last quarter:
Inari Medical Announces Results From The Fully Enrolled 800-patient US Cohort Of The FlowTriever FLASH Registry
Inari Medical, Inc. (NASDAQ:NARI) ("Inari") a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive